|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/04/20 Acadia Pharmaceuticals Inc. 10-Q 9/30/20 60:7.1M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 897K
2: EX-10.1 Material Contract HTML 40K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
13: R1 Document and Entity Information HTML 71K
14: R2 Condensed Consolidated Balance Sheets HTML 102K
15: R3 Condensed Consolidated Balance Sheets HTML 36K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 71K
(Unaudited)
17: R5 Condensed Consolidated Statements of Comprehensive HTML 38K
Loss
18: R6 Condensed Consolidated Statements of Cash Flows HTML 106K
(Unaudited)
19: R7 Condensed Consolidated Statements of Stockholders' HTML 60K
Equity (Unaudited)
20: R8 Organization and Business HTML 22K
21: R9 Basis of Presentation and Significant Accounting HTML 60K
Policies
22: R10 Net Loss Per Share HTML 22K
23: R11 Stock-Based Compensation HTML 55K
24: R12 Balance Sheet Details HTML 69K
25: R13 Investments HTML 226K
26: R14 Fair Value Measurements HTML 138K
27: R15 Stockholders' Equity HTML 23K
28: R16 Commitments and Contingencies HTML 46K
29: R17 Recent Accounting Pronouncements HTML 26K
30: R18 Leases HTML 105K
31: R19 Basis of Presentation and Significant Accounting HTML 79K
Policies (Policies)
32: R20 Basis of Presentation and Significant Accounting HTML 50K
Policies (Tables)
33: R21 Stock-Based Compensation (Tables) HTML 56K
34: R22 Balance Sheet Details (Tables) HTML 71K
35: R23 Investments (Tables) HTML 221K
36: R24 Fair Value Measurements (Tables) HTML 134K
37: R25 Leases (Tables) HTML 108K
38: R26 Basis of Presentation and Significant Accounting HTML 29K
Policies - Schedule of Reconciliation of Cash,
Cash Equivalents and Restricted Cash (Detail)
39: R27 Basis of Presentation and Significant Accounting HTML 30K
Policies - Additional Information (Detail)
40: R28 Net Loss Per Share - Additional Information HTML 21K
(Detail)
41: R29 Stock-Based Compensation - Summary of Stock-based HTML 30K
Compensation Expense Included in Statements of
Operations (Detail)
42: R30 Balance Sheet Details - Schedule of Inventory HTML 28K
(Detail)
43: R31 Balance Sheet Details - Schedule of Accrued HTML 37K
Liabilities (Detail)
44: R32 Investments - Carrying Value and Amortized Cost of HTML 60K
Company's Investments Summarized by Major Security
Type (Detail)
45: R33 Investments - Carrying Value and Amortized Cost of HTML 23K
Company's Investments Summarized by Major Security
Type (Parenthetical) (Detail)
46: R34 Investments - Additional Information (Detail) HTML 25K
47: R35 Investments - Summary of Gross Unrealized Losses HTML 38K
and Fair Value of Available-For-Sale Investment
Securities in Unrealized Loss Position (Detail)
48: R36 Investments - Summary of Gross Unrealized Losses HTML 23K
and Fair Value of Available-For-Sale Investment
Securities in Unrealized Loss Position
(Parenthetical) (Detail)
49: R37 Fair Value Measurements - Fair Value Measurements HTML 47K
of Cash Equivalents, Available-For-Sale Investment
Securities and Equity Securities (Detail)
50: R38 Stockholders' Equity - Additional Information HTML 34K
(Detail)
51: R39 Commitments and Contingencies - Additional HTML 94K
Information (Detail)
52: R40 Leases - Additional Information (Detail) HTML 62K
53: R41 Leases - Summary of Operating Lease Costs (Detail) HTML 21K
54: R42 Leases - Supplemental Cash Flow Information HTML 23K
Related to the Company's Leases (Detail)
55: R43 Leases - Summary of Balance Sheet Classification HTML 27K
of Lease Liabilities (Detail)
56: R44 Leases - Summary of Maturities of Lease HTML 40K
Liabilities (Detail)
58: XML IDEA XML File -- Filing Summary XML 105K
12: XML XBRL Instance -- acad-10q_20200930_htm XML 1.71M
57: EXCEL IDEA Workbook of Financial Reports XLSX 63K
8: EX-101.CAL XBRL Calculations -- acad-20200930_cal XML 153K
9: EX-101.DEF XBRL Definitions -- acad-20200930_def XML 256K
10: EX-101.LAB XBRL Labels -- acad-20200930_lab XML 774K
11: EX-101.PRE XBRL Presentations -- acad-20200930_pre XML 566K
7: EX-101.SCH XBRL Schema -- acad-20200930 XSD 117K
59: JSON XBRL Instance as JSON Data -- MetaLinks 251± 389K
60: ZIP XBRL Zipped Folder -- 0001564590-20-050566-xbrl Zip 198K
 | Download this zipped .zip folder |
| Files: | acad-10q_20200930.htm acad-20200930.xsd acad-20200930_cal.xml acad-20200930_def.xml acad-20200930_lab.xml acad-20200930_pre.xml acad-ex101_114.htm acad-ex311_7.htm acad-ex312_9.htm acad-ex321_8.htm acad-ex322_6.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Acadia Pharmaceuticals Inc. 10-K 12/31/23 88:14M Donnelley … Solutions/FA 2/28/23 Acadia Pharmaceuticals Inc. 10-K 12/31/22 79:15M Donnelley … Solutions/FA 3/01/22 Acadia Pharmaceuticals Inc. 10-K 12/31/21 82:13M Donnelley … Solutions/FA 2/25/21 Acadia Pharmaceuticals Inc. 10-K 12/31/20 80:13M ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/27/19 Acadia Pharmaceuticals Inc. 10-K 12/31/18 71:13M ActiveDisclosure/FA 8/06/15 Acadia Pharmaceuticals Inc. 10-Q 6/30/15 43:1.7M Donnelley … Solutions/FA 9/12/13 Acadia Pharmaceuticals Inc. 8-K:5 9/06/13 2:179K SEC Connect 12/21/00 Acadia Pharmaceuticals Inc. S-1 28:1.7M Toppan Merrill-FA2/FA |